Corporate support helps the GI Cancer Institute unlock the answers to better treatments for the 34,291 Australians diagnosed with gastro-intestinal (GI) cancer each year.
With 38 Australians losing their lives to the disease every day, the stakes are high.
The GI Cancer Institute aims to raise money for GI cancer clinical trials research conducted by the Australasian Gastro-Intestinal Trials Group (AGITG). The AGITG is comprised over 1,600 medical professionals who volunteer their time. AGITG research is conducted independently of the corporate supporters of the GI Cancer Institute.
We thank the following companies for their recent support.
Corporate Sponsor – Platinum
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory & Autoimmunity, Cardiovascular & Metabolic Disease and Oncology.
The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Corporate Sponsors – Gold
The Pierre Fabre Group, founded by a pharmacist Pierre Fabre, is the second largest private pharmaceutical company in France. Owned by a government recognised public interest foundation, the Group is committed to designing and developing innovative solutions to contribute to the wellbeing of everyone through products across consumer health, dermo-cosmetics and pharmaceuticals. In Australia, Pierre Fabre has prescription medicines in the area of oncology, dermo-cosmetics brand Eau Thermale Avène (a skincare range for all forms of sensitive skin), and Klorane (a haircare range formulated from carefully selected botanical ingredients). For more information visit: www.pierre-fabre.com/en-au
Amgen is committed to unlocking the potential of biology for patients suffering from serious illness by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.